1 Castrejon I, Tani C, Jolly M, Huang A, Mosca M .Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 2014; 85: S-85-95.
2 Miles A, Pope Je. A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE. Clin Exp Rheumatol. 2015; 33: 671-680.
3 Fatemi A, Raeisi A, Sayedbonakdar Z, Smiley A. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study. Clin Rheumatol. 2018; 37: 955-962.
4 Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken). 2011; 63: S37-S46.
5 Liu Y, Peng L, Li L, Liu C, Hu X, Xiao S et al. TWEAK/Fn14 activation contributes to the pathogenesis of bullous pemphigoid. J Invest Dermatol. 2017; 137: 1512-1522.
6 Cheng H, Zhan N, Ding D, Liu X, Zou X, Li K et al. HPV type 16 infection switches keratinocytes from apoptotic to proliferative fate under TWEAK/Fn14 interaction. J Invest Dermatol. 2015; 135: 2427-2436.
7 Cheng H, Xu M, Liu X, Zou X, Zhan N, Xia Y. TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation. Exp Dermatol. 2016; 25: 32-37.
8 Hu G, Zeng W, Xia Y. TWEAK/Fn14 signaling in tumors. Tumor Biol. 2017; 39: 1010428317714624.
9 Liu Q, Xiao S, Xia Y. TWEAK/Fn14 activation participates in skin inflammation. Mediators Inflamm. 2017; 2017: 6746870.
10 Liu Y, Xu M, Min X, Wu K, Zhang T, Li K et al. TWEAK/Fn14 activation participates in Ro52-mediated photosensitization in cutaneous lupus erythematosus. Front Immunol. 2017; 8: 651.
11 Doerner J, Wen J, Xia Y, Paz KB, Schairer D, Wu L et al. TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus. J Invest Dermatol. 2015; 135: 1986-1995.
12 Xia Y, S Campbell R, Broder A, Herlitz L, Abadi M, Wu P et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin. Immunol. 2012; 145: 108-121.
13 Xia Y, Herlitz Lc, Gindea S, Wen J, Pawar RD, Misharin A et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol. 2015; 26: 1053-1070.
14 Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun. 2013; 43: 44-54.
15 Wen J, Doerner J, Weidenheim K, Xia Y, Stock A, Michaelson JS et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun. 2015; 60: 40-50.
16 Xu Wd, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res. 2016; 64: 44-50.
17 Xia Y, Pawar Rd, Nakouzi As, Herlitz L, Broder A, Liu K et al. The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies. J Autoimmun. 2012; 9: 398-411.
18 Liu Zc, Zhou Ql, Li Xz, Yang JH, Ao X, Veeraragoo P et al. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine. 2011; 53: 295-300.
19 Choe Jy, Kim Sk. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus. Inflamm Res. 2016; 65: 479-488.
20 Fragoso-Loyo H, Atisha-Fregoso Y, Nuñez-Alvarez Ca, Llorente L. Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erhytematosus. Lupus. 2016; 25: 364-369.
21 Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol. 2012; 2012: 359647.
22 Sládková T, Kostolanský F. The role of cytokines in the immune response to influenza A virus infection. Acta Virol. 2006; 50: 151-162.
23 Martynowicz H, Janus A, Nowacki D, Mazur G. The role of chemokines in hypertension. Adv Clin Exp Med. 2014; 23: 319-325.
24 Zhang Yp, Wu J, Han Yf, Shi Zr, Wang L. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema. Autoimmun Rev. 2017; 16: 735-742.
25 Dima A, Opris D, Jurcut C, Baicus C. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus. 2016; 25: 1173-1179.
26 Zhang Y, Yang J, Jiang S, Fang C, Xiong L, Cheng H et al. The lupus-derived anti-double-stranded DNA IgG contributes to myofibroblast-like phenotype in mesangial cells. J Clin Immunol. 2012; 32: 1270-1278.
27 Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2018; 30: 482-489.
28 Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009; 18: 257-263.